Cargando…
European Society of Cardiology Highlights: Late-breaking Trials – COVID-19
Autores principales: | Komiyama, Maki, Hasegawa, Koji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Radcliffe Cardiology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900137/ https://www.ncbi.nlm.nih.gov/pubmed/35284005 http://dx.doi.org/10.15420/ecr.2022.03 |
Ejemplares similares
-
Response to the Comment ‘Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019
por: Komiyama, Maki, et al.
Publicado: (2020) -
Anticoagulant Therapy for Patients with Coronavirus Disease 2019: Urgent Need for Enhanced Awareness
por: Komiyama, Maki, et al.
Publicado: (2020) -
Smoking Cessation as a Public Health Measure to Limit the Coronavirus Disease 2019 Pandemic
por: Komiyama, Maki, et al.
Publicado: (2020) -
Coronavirus Disease 2019: Psychological Stress and Cardiovascular Diseases
por: Komiyama, Maki, et al.
Publicado: (2021) -
Dilated Cardiomyopathy Risk in Patients with Coronavirus Disease 2019: How to Identify and Characterise it Early?
por: Komiyama, Maki, et al.
Publicado: (2020)